ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 61 filers reported holding ADC THERAPEUTICS SA in Q1 2023. The put-call ratio across all filers is 16.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,717,706 | -57.9% | 14,178,045 | +0.9% | 0.60% | -47.8% |
| Q2 2023 | $30,207,360 | +14.2% | 14,049,935 | +3.6% | 1.16% | +1.0% |
| Q1 2023 | $26,452,236 | -9.3% | 13,565,249 | +78.7% | 1.15% | -3.7% |
| Q4 2022 | $29,148,860 | -19.5% | 7,590,849 | +1.0% | 1.19% | -15.1% |
| Q3 2022 | $36,208,000 | -39.4% | 7,512,029 | 0.0% | 1.40% | -38.4% |
| Q2 2022 | $59,721,000 | -45.3% | 7,512,029 | +1.1% | 2.28% | -33.1% |
| Q1 2022 | $109,182,000 | -27.5% | 7,432,429 | -0.2% | 3.41% | -0.4% |
| Q4 2021 | $150,511,000 | -26.4% | 7,451,029 | -1.0% | 3.42% | -4.1% |
| Q3 2021 | $204,497,000 | +11.6% | 7,529,329 | +0.1% | 3.57% | +31.6% |
| Q2 2021 | $183,161,000 | +2.7% | 7,522,029 | +2.9% | 2.71% | +7.8% |
| Q1 2021 | $178,398,000 | -17.5% | 7,308,418 | +8.1% | 2.51% | -4.1% |
| Q4 2020 | $216,349,000 | +3.2% | 6,758,794 | +6.4% | 2.62% | -31.9% |
| Q3 2020 | $209,589,000 | -19.0% | 6,353,094 | +15.0% | 3.85% | -19.4% |
| Q2 2020 | $258,666,000 | – | 5,525,870 | – | 4.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $4,555,066 | 2.69% |
| Blue Owl Capital Holdings LP | 733,568 | $2,816,901 | 1.20% |
| Redmile Group, LLC | 7,590,849 | $29,148,860 | 1.19% |
| AlphaCentric Advisors LLC | 297,500 | $1,142,400 | 1.13% |
| Prosight Management, LP | 463,310 | $1,779,110 | 0.97% |
| GCM Grosvenor Holdings, LLC | 735,471 | $2,824,209 | 0.72% |
| Indie Asset Partners, LLC | 93,839 | $360,342 | 0.40% |
| XTX Topco Ltd | 197,635 | $758,918 | 0.16% |
| Eventide Asset Management | 1,879,959 | $7,219,043 | 0.14% |
| Nantahala Capital Management | 243,290 | $934,234 | 0.06% |